Dx at heart of high-profile NHS drug approval
This article was originally published in Clinica
Executive Summary
It is extremely rare that a high-profile approval of a pharmaceutical for NHS use is as dependent on diagnostic testing and monitoring as that of Herceptin, as recommended today by the National Institute for Health and Clinical Excellence (NICE). According to the draft guidance, the use of trastuzumab for early HER2-positive breast cancer will be subject to tight cardiac function parameters that are to be assessed prior to treatment, and then every three months.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.